There are several selective small molecule inhibitors of DOT1L, including EPZ-5676, which is currently under clinical evaluation for treating MLL- rearranged leukemia (ClinicalTrials.gov identifier NCT02141828). The gene discussed is DOT1L; the disease is leukemia.